Free Trial

Eddie Hickman Analyst Performance

Vice President at Guggenheim

Eddie Hickman is a stock analyst at Guggenheim focused in the medical sector, covering 7 publicly traded companies. Over the past year, Eddie Hickman has issued 12 stock ratings, including buy and hold recommendations. While full access to Eddie Hickman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Eddie Hickman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
20 Last 1 Years
Buy Recommendations
95.00% 19 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy95.0%19 ratings
Hold5.0%1 ratings
Sell0.0%0 ratings

Out of 20 total stock ratings issued by Eddie Hickman at Guggenheim, the majority (95.0%) have been Buy recommendations, followed by 5.0% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
7 companies

Eddie Hickman, an analyst at Guggenheim, currently covers 7 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
6 companies
85.7%
Manufacturing
1 company
14.3%

Eddie Hickman of Guggenheim specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
4 companies
57.1%
MED - OUTP/HM CRE
1 company
14.3%
MED - DRUGS
1 company
14.3%
Miscellaneous
1 company
14.3%

Eddie Hickman's Ratings History at Guggenheim

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
4/17/2026Boost Price Target$4.09$16.00Buy
GH Research PLC stock logo
GHRS
GH Research
3/10/2026Set Price Target$15.83$34.00Buy
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
3/10/2026Set Price Target$11.05$23.00Buy
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
2/25/2026Boost Price Target$73.63$90.00Buy
Promis Neurosciences stock logo
PMN
Promis Neurosciences
2/6/2026Lower Price Target$13.26$35.00Buy
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
1/20/2026Initiated Coverage$3.64$11.00Buy
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
1/20/2026Initiated Coverage$3.90$11.00Buy
GH Research PLC stock logo
GHRS
GH Research
1/5/2026Reiterated Rating$15.75$29.00Buy
Cybin Inc. stock logo
HELP
Cybin
12/3/2025Boost Price Target$5.72$48.00Buy
Promis Neurosciences stock logo
PMN
Promis Neurosciences
11/18/2025Lower Price Target$8.80$125.00Buy
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
11/5/2025Boost Price Target$69.39$87.00Buy
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
8/28/2025Downgrade$1.10Neutral
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
5/2/2025Boost Price Target$48.54$84.00Buy
Promis Neurosciences stock logo
PMN
Promis Neurosciences
4/1/2025Reiterated Rating$18.13$150.00Buy
Cybin Inc. stock logo
HELP
Cybin
3/13/2025Initiated Coverage$7.34$35.00Buy
GH Research PLC stock logo
GHRS
GH Research
3/13/2025Initiated Coverage$11.35$32.00Buy
Promis Neurosciences stock logo
PMN
Promis Neurosciences
2/26/2025Reiterated Rating$0.72Buy
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
2/24/2025Reiterated Rating$46.72$78.00Buy
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
2/10/2025Reiterated Rating$52.48Buy
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
1/17/2025Reiterated Rating$2.19$12.00Buy